Leqvio with 'twice-yearly treatment' set for mkt
By Whang, byung-woo | translator Hong, Ji Yeon
24.11.15 05:21:35
가나다라
0
Launched in the market on Nov.11, DC review process is in progress in general hospitals
Although it hasn't been announced yet, Novartis is anticipated to utilize in-house sales and co-promotion in KOR
Securing reimbursement is the company's priority, given a competing drug…aims to negotiate with the government for around KRW 3 million
Leqvio is set to challenge the market with its superior drug tolerance, administered twice yearly, compared to existing treatments.
▲Product photo of Leqvio.
According to the pharmaceutical industry on November 15, Novartis Korea launched the siRNA therapy Leqvio (inclisiran) on November 11.Lecvio is the first-in-class siRNA drug approved in South Korea. It is approved as an adjunct to dietary therapy for patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia.
Leqvio uses naturally occurring siRNA to block PCSK9 protein production and lower LDL cholesterol levels. It has the advantage of its twice-yearly administration by doctors, reducing the cha
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)